Provided by Tiger Trade Technology Pte. Ltd.

Artelo Biosciences, Inc.

4.04
-0.0300-0.74%
Pre-market: 4.090.0500+1.24%06:02 EDT
Volume:68.47K
Turnover:280.12K
Market Cap:2.21M
PE:-0.04
High:4.30
Open:4.06
Low:3.95
Close:4.07
52wk High:179.19
52wk Low:3.45
Shares:547.78K
Float Shares:547.42K
Volume Ratio:0.01
T/O Rate:12.51%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-102.4151
EPS(LYR):-337.9329
ROE:-705.71%
ROA:-127.92%
PB:0.44
PE(LYR):-0.01

Loading ...

Artelo Biosciences - Art26.12 Shows Efficacy Comparable to Naproxen in Nonclinical Osteoarthritis Study

THOMSON REUTERS
·
Jul 16

Artelo Biosciences Announces Annual Shareholder Meeting

Reuters
·
Jul 14

Artelo Biosciences Reports Positive Preclinical Data for Art27.13 in Paclitaxel-induced Peripheral Neuropathy Model

Reuters
·
Jul 13

Artelo Biosciences - Interim Results Show Improved Body Weight, Lean Mass, Activity, and Safety up to 1300 Μg/day

THOMSON REUTERS
·
Jul 13

Artelo Biosciences - Art27.13 Reduces Neuropathic Pain Behaviors in Paclitaxel-treated Animals

THOMSON REUTERS
·
Jul 13

SK Hynix's Landmark Nasdaq Debut Bets on AI Reshaping Memory Chip Industry's Boom-Bust Cycle

Deep News
·
Jul 11

SK hynix's $26.5 Billion Nasdaq Debut: A Test for Overcoming the 'Korea Discount'

Stock News
·
Jul 10

Artelo Biosciences presents preclinical pain data for ART26.12

TIPRANKS
·
Jul 01

Artelo Biosciences Reports Positive Preclinical Data for Art26.12 in Spinal Cord Injury Neuropathic Pain Model

Reuters
·
Jul 01

Artelo Biosciences Announces New Data Supporting Art26.12 as a Potential First-in-class Therapy for Chronic Pain Associated with Spinal Cord Injury

THOMSON REUTERS
·
Jul 01

Artelo Biosciences Says Phase 1 FABP5 Inhibitor Art26.12 Study Shows Linoleic Acid Signaling Link Across Disease Models

Reuters
·
Jun 30

Bitcoin Mining Firm Ionic Digital Files for Direct Listing on Nasdaq

Stock News
·
Jun 30

Artelo Biosciences Says Phase 1 Study Shows FABP5 Inhibitor Art26.12 is Well Tolerated, with Linear Pharmacokinetics

Reuters
·
Jun 29

Bank of America Issues Warning: Nasdaq Reaches "Bubble Threshold" Driven by Semiconductors

Deep News
·
Jun 25

U.S. Markets Open Mixed as Focus Turns to SpaceX Nasdaq Debut

Deep News
·
Jun 12

Artelo Biosciences reports favorable human metabolite profile for ART26.12 in completed SAD trial

Reuters
·
Jun 10

Artelo Biosciences Launches Flexible At-The-Market Offering

TIPRANKS
·
May 28

Top Premarket Decliners

MT Newswires Live
·
May 27

Artelo Biosciences announces annual shareholder meeting

Reuters
·
May 27

Artelo Biosciences Inc - to Offer up to $6.53 Mln in Common Stock via H.c. Wainwright - SEC Filing

THOMSON REUTERS
·
May 27